BioCentury | Jul 26, 2018
Company News

Reese succeeding Harper as Amgen EVP of R&D

...#), denosumab (Generic), Xgeva (Other), Ranmark (Other), Prolia (Other), Pralia (Other) Amgen Inc. Bristol-Myers Squibb Co. CD3 Erythropoietin (EPO) receptor Lymphotoxin alpha Proprotein...
BioCentury | Jul 7, 2017
Clinical News

Daiichi ends Japanese development of Coherus' Enbrel biosimilar

...CHS-0214 , BAX 2200) Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha ; Lymphotoxin alpha...
...Endpoint: NA Status: Development discontinued Milestone: NA Jaime De Leon BAX 2200 CHS-0214 Enbrel Amgen Inc. Coherus BioSciences Inc. Daiichi Sankyo Co. Ltd. Lymphotoxin alpha Tumor...
BioCentury | Jul 5, 2017
Company News

Daiichi ends development of Coherus' biosimilar of Enbrel

...BioCentury Extra, June 12) . Jaime De Leon BAX 2200 Biosimilar rituxan CHS-0214 Enbrel IDEC-C2B8 MabThera R105 RG105 Rituxan rituximab Amgen Inc. Biogen Inc. Coherus BioSciences Inc. Daiichi Sankyo Co. Ltd. Roche Lymphotoxin alpha Tumor...
BioCentury | Apr 14, 2017
Company News

Inovalon, Amgen deal

...NASDAQ:INOV), Bowie, Md. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Autoimmune Jaime De Leon Enbrel Amgen Inc. Inovalon Holdings Inc. Lymphotoxin alpha Tumor...
BioCentury | Dec 21, 2016
Clinical News

Lifmior regulatory update

...human IgG1 (TNFr:Fc). Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lifmior etanercept Business: Autoimmune Alicia Parker Pfizer Inc. Lymphotoxin alpha Tumor...
BioCentury | Dec 16, 2016
Company News

Celltrion biosimilar among CHMP recommendations

...Corp. Merck & Co. Inc. Pfizer Inc. Roche Anaplastic lymphoma kinase (ALK) Clostridium difficile toxin B (TcdB) Janus kinase-1 (JAK-1) Janus kinase-2 (JAK-2) Lymphotoxin alpha Programmed...
BioCentury | Jan 18, 2016
Clinical News

CHS-0214: Phase III data

...Product: CHS-0214 , BAX 2200 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha ; Lymphotoxin alpha...
BioCentury | Nov 16, 2015
Clinical News

CHS-0214: Phase III data

...Product: CHS-0214 , BAX 2200 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha ; Lymphotoxin alpha...
BioCentury | Jun 1, 2015
Clinical News

CHS-0214: Completed Phase III enrollment

...Tokyo:4568), Tokyo, Japan Product: CHS-0214 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha ; Lymphotoxin alpha...
BioCentury | Jun 1, 2015
Clinical News

CHS-0214: Completed Phase III enrollment

...Tokyo:4568), Tokyo, Japan Product: CHS-0214 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha ; Lymphotoxin alpha...
Items per page:
1 - 10 of 47